论文部分内容阅读
目的观察重组链激酶(r-SK)与尿激酶(UK)静脉溶栓治疗急性心肌梗死的疗效。方法将93患者随机分成r-SK组48例和UK组45例,均给常规治疗,r-SK组,r-SK150万单位+5%葡萄糖100mL;UK组,UK150万单位+5%葡萄糖100mL,观察冠状动脉再通率、不良反应及5周病死率。结果r-SK组总再通率81.25%,6h内再通率为86.49%,与UK组比较,差异均有统计学意义(P<0.05);2组在出血、心律失常、过敏、低血压及5周后死亡率上,差异无统计学意义(P>0.05)。结论r-SK较UK的心肌梗死血管再通率高,药效较好,也具有不良反应和并发症少的特点,是值得临床上推广应用。
Objective To observe the curative effect of intravenous thrombolytic therapy of recombinant streptokinase (r-SK) and urokinase (UK) on acute myocardial infarction. Methods Ninety-three patients were randomly divided into r-SK group (n = 48) and UK group (n = 45). All of the patients were given conventional therapy, r-SK group, r-SK150 million units + 5% glucose 100 mL; UK group; UK1.5 million units + 5% glucose 100 mL , Observe the rate of coronary recanalization, adverse reactions and 5-week mortality. Results The total recanalization rate was 81.25% in r-SK group and the recanalization rate was 86.49% in 6 hours, which was significantly different from that in UK group (P <0.05). The incidence of hemorrhage, arrhythmia, allergy, hypotension And 5 weeks after the death rate, the difference was not statistically significant (P> 0.05). Conclusions r-SK is better than UK in the rate of recanalization of myocardial infarction, better efficacy, less adverse reactions and fewer complications, which is worthy of clinical application.